The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
An overview of quinoline as a privileged scaffold in cancer drug discovery
Abstract
INTRODUCTION: The concept of privileged structures is well known and is often used in the process of drug design and development. Although its assumptions are not clear, its overall usefulness remains high. Various substructures have been identified as privileged and quinoline is a prime example of such a structure. Areas covered: Quinoline drugs that are currently approved or under clinical investigation were reviewed based on a literature search. Their modes of action and outcomes during clinical research are discussed. Expert opinion: Undoubtedly, quinoline-based compounds have a significant impact on anticancer drugs. Although topoisomerase and kinase inhibitors are the only two different classes of agents that are currently approved for anticancer therapy, more than twenty different drug candidates are being tested on humans. The quinoline moiety offers an easily accessible, well-understood scaffold for designing new drugs. It is also a very druggable molecule with the potency for structure optimization through established synthetic pathways. For these reasons, quinoline-based anticancer drugs have a strong position in modern medicinal chemistry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“As is shown by the structural research for bosutinib, the quinoline nitrogen interacts with methionine in ABL kinase [194], while similar interactions with methionine in EGFR have been observed in neratinib [195,196].”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Privileged scaffolds for library design and drug discovery
Welsch, M. E., Snyder, S. A., & Stockwell, B. R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.02.018 · Cited by 1,509
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Larsen, P. O., & von Ins, M. (2010) · Scientometrics · doi:10.1007/s11192-010-0202-z · Cited by 964
Antimicrobial Activities of Mefloquine and a Series of Related Compounds
Kunin, C. M., & Ellis, W. Y. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.848-852.2000 · Cited by 100
Cited by
Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry
Yadav, P., & Shah, K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104639 · Cited by 286
Shang, F.-F., Wang, J. Y., Xu, Q., Deng, H., Guo, H.-Y., Jin, X., Li, X., Shen, Q.-K., & Quan, Z.-S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113474 · Cited by 30
Metadata
- Authors
- Musiol, R.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2017-04-20
- Volume
- 12
- Issue
- 6
- Pages
- 583-597
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2605478093
- Cited by
- 246
- References
- 6
- FWCI
- 7.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An overview of quinoline as a privileged scaffold in cancer drug discovery. https://app.cochat.ai/papers/10.1080/17460441.2017.1319357
- The paper
- Musiol, R. (2017). An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2017.1319357
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.